

CONCERNED ABOUT THE FLU? AGED 65 OR OLDER?

The annual flu season is here.
How can you help protect
yourself?

FLU FACTS:

- ▲ Seniors aged 65 and older have the highest rate of hospitalization and death.
- ▲ Seniors, particularly those with chronic medical conditions – such as heart or lung disease, or diabetes – may be at increased risk of complications from the flu, such as pneumonia or respiratory distress.

Getting the seasonal flu vaccine is a generally safe,
long-lasting and effective way to reduce the risk of influenza.

IF YOU ARE 65 OR OLDER, GET YOUR ANNUAL FLU VACCINATION WITH Fluad®

– A VACCINE SPECIFICALLY DESIGNED FOR SENIORS.

“Among adults aged 65 or older, studies show that regular vaccine effectiveness is about half of that of healthy adults.”

YOUR SEASONAL PARTNER AGAINST THE FLU

- ▶ FLUAD® is an influenza virus vaccine specifically designed for adults aged 65 or older to help keep people from developing the flu or to reduce flu symptoms.
 - FLUAD® will not treat influenza or its complications, including related-hospitalizations and death, and does not protect against the common cold.
- ▶ FLUAD® contains an adjuvant:
 - An adjuvant is a substance that is added to a vaccine to enhance the immune response.
- ▶ FLUAD® significantly increases your immune response vs. a standard vaccine (without adjuvant)
- ▶ Only one dose of FLUAD® is required and it can be given at the same time as other vaccines.
- ▶ Keep in mind it takes 2-3 weeks after vaccination for your body to develop protection against the flu.

FLUAD® is backed by a long history of global experience, with more than 90 million doses distributed worldwide since 1997.

FLUAD® is generally well tolerated. The most common side effects are pain, redness, or swelling at the injection site, fever, feeling unwell, shivering, tiredness, headache, sweating, and muscle and joint pain and warmth. Side effects normally disappear without treatment after a day or two. Allergic reactions may occur.

FLUAD® should not be used in patients with a history of hypersensitivity to egg proteins or other components of the vaccine, any of the non-medicinal ingredients or in people who have had a life-threatening reaction to previous influenza vaccination. As with any vaccine, FLUAD® may not protect 100% of individuals against the flu. If Guillain-Barré syndrome has occurred within six weeks of previous influenza vaccination, the decision to give FLUAD® should be based on careful consideration of the potential benefits and risks.

Please visit www.seqirus.ca for complete product information.

References: **1.** Public Health Agency of Canada. Who is more at risk of complications from the flu? Available at <http://www.fightflu.ca/risk-risque-eng.php> Accessed June 5, 2014. **2.** WebMD. Flu and Chronic Medical Conditions. Flu Guide. Available at www.webmd.com/cold-and-flu/flu-guide/fact-sheet-chronic-conditions. Accessed June 5, 2014. **3.** An Advisory Committee Statement (ACS). National Advisory Committee on Immunization (NACI). Statement on Seasonal Influenza Vaccine for 2014-2015. Canada Communicable Disease Report. 2014, Volume 40:1-70. **4.** FLUAD® Product Monograph. Seqirus Pharmaceuticals Canada Inc., May 7, 2014. **5.** Canadian Immunization Guide Part 1- Key Immunization Information 2013. Basic Immunology and Vaccinology. Available at <http://www.phac-aspc.gc.ca/publicat/cig-gci/p01-13-eng.php>. Accessed August 26, 2014. **6.** Data on File. Seqirus Pharmaceuticals Canada Inc.

Seqirus Canada Inc.
Kirkland, Québec
www.seqirus.ca
☎ 1-844-392-8582
☎ 514-221-4877


A CSL Company

FLUAD is a registered trademark of Seqirus UK Limited or its affiliates.
CA/FTI/0517/0002E


(influenza vaccine, surface antigen, inactivated, adjuvanted with MF59C.1)